Hims & Hers Health reported second quarter 2026 revenue of $753.2 million, exceeding consensus estimates by approximately 8%. However, the company posted a significant EPS miss with a net loss of $0.37 per share compared to the $0.07 loss expected by analysts. The earnings result was heavily impacted by $33.1 million in non-recurring restructuring charges related to the pivot in its weight loss segment and integration costs from the Eucalyptus acquisition.
Key Highlights
- Total revenue rose 38% year-over-year to $753.2 million, driven by a 17-fold surge in international revenue to $131.4 million following the Eucalyptus acquisition.
- Gross margin contracted significantly to 64% from 76% in the prior-year period, pressured by higher costs associated with branded GLP-1 medications and $28.5 million in non-cash restructuring charges.
- Management raised full-year 2026 revenue guidance to a range of $3.1 billion to $3.3 billion, representing a substantial increase from the previous $2.8 billion to $3.0 billion outlook.
- The subscriber base expanded 19% year-over-year to nearly 2.9 million, though monthly revenue per average subscriber saw a more modest 4% increase year-to-date.